Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Osiris Therapeutics (OTHER OTC: OSIR)

$4.85 USD $0.06 (1.25%)
Last Price $4.85
Net Change $0.06 (1.25%)
Bid $0
Ask Price $0
Open Price $4.695
Previous Close Price $4.79
High Price $4.85
Low Price $4.695
Number of Trades 66
Volume 75,517
Fifty Two Week High $7.39 (2016-11-11)
Fifty Two Week Low $2.67 (2017-03-15)
Average Daily Volume 186,858
Share Outstanding 34,530 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $ ()
2nd Quarter Earnings $ ()
3nd Quarter Earnings $ ()
4th Quarter Earnings $ ()
PE Ratio $0
EPS Growth $0
Recent Earnings $
Annual EPS $0
Last Quarter EPS $
Market Capitalization $0.17B
Insider Shareholders % 0.446%
Annual Revenue $0B
No. Shares Outstanding 34,530
Inst. Shareholder % 16.21%
Annual Net Income $0B
TTM Net Profit Margin $100
1-Year Return -21.35%
3-Year Return -64.36%
5-Year Return -12.75%
5-Year Revenue Growth 0%
5-Year Earnings Growth 0%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD %
Dividends per Share $
Stock Split Ratio
Beta 0.93
OSIRIS THERAPEUTICS, INC. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel for regenerating bone in orthopedic indications. Prochymal is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease and also Crohn's disease, and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. Osiris also has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. Osiris is a fully integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products.

OSIR News & Stock Updates